Emerging roles of N6-methyladenosine (m6A) modification in breast cancer

被引：25
作者：
Wang, Yanyan [1 ]
Zhang, Yujie [2 ]
Du, Yushen [3 ]
Zhou, Meiqi [1 ]
Hu, Yue [1 ]
Zhang, Suzhan [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 2, Dept Breast Surg, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Dept Orthped Surg, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China
[3] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
来源：
CELL AND BIOSCIENCE | 2020年 / 10卷 / 01期
关键词：
m(6)A; Breast cancer; Epigenetics; Molecular mechanism; Clinical applications; PRE-MESSENGER-RNA; METTL3; PROMOTES; METHYLATION; OBESITY; FTO; MECHANISMS; TRANSCRIPTOME; DEMETHYLASE; REGULATORS; RESOLUTION;
D O I：
10.1186/s13578-020-00502-3
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
N6-Methyladenosine (m(6)A) is the most abundant, dynamic, and reversible epigenetic RNA modification that is found in coding and non-coding RNAs. Emerging studies have shown that m(6)A and its regulators affect multiple steps in RNA metabolism and play broad roles in various cancers. Worldwide, breast cancer is the most prevalent cancer in female. It is a very heterogeneous disease characterized by genetic and epigenetic variations in tumor cells. Increasing evidence has shown that the dysregulation of m(6)A-related effectors, as methyltransferases, demethylases, and m(6)A binding proteins, is pivotal in breast cancer pathogenesis. In this review, we have summarized the most up-to-date research on the biological functions of m(6)A modification in breast cancer and have discussed the potential clinical applications and future directions of m(6)A modification as a biomarker as well as a therapeutic target of breast cancer.
引用
收藏
页数：11
相关论文
共 110 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Current Landscape of Immunotherapy in Breast Cancer: A Review [J].
Adams, Sylvia ;
Gatti-Mays, Margaret E. ;
Kalinsky, Kevin ;
Korde, Larissa A. ;
Sharon, Elad ;
Amiri-Kordestani, Laleh ;
Bear, Harry ;
McArthur, Heather L. ;
Frank, Elizabeth ;
Perlmutter, Jane ;
Page, David B. ;
Vincent, Benjamin ;
Hayes, Jennifer F. ;
Gulley, James L. ;
Litton, Jennifer K. ;
Hortobagyi, Gabriel N. ;
Chia, Stephen ;
Krop, Ian ;
White, Julia ;
Sparano, Joseph ;
Disis, Mary L. ;
Mittendorf, Elizabeth A. .
JAMA ONCOLOGY, 2019, 5 (08) :1205-1214
[3]   FTO Gene Affects Obesity and Breast Cancer Through Similar Mechanisms: A New Insight into the Molecular Therapeutic Targets [J].
Akbari, M. E. ;
Gholamalizadeh, M. ;
Doaei, S. ;
Mirsafa, F. .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2018, 70 (01) :30-36
[4]   N6-methyladenosine marks primary microRNAs for processing [J].
Alarcon, Claudio R. ;
Lee, Hyeseung ;
Goodarzi, Hani ;
Halberg, Nils ;
Tavazoie, Sohail F. .
NATURE, 2015, 519 (7544) :482-+
[5]  
An S, 2020, Res, V48, P1715, DOI [10.1093/nar/gkz1206, DOI 10.1093/NAR/GKZ1206]
[6]   Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease [J].
Bianchini, Giampaolo ;
Balko, Justin M. ;
Mayer, Ingrid A. ;
Sanders, Melinda E. ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (11) :674-690
[7]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[8]   HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g [J].
Cai, Xiaoli ;
Wang, Xiao ;
Cao, Can ;
Gao, Yuen ;
Zhang, Shuqin ;
Yang, Zhe ;
Liu, Yunxia ;
Zhang, Xiaodong ;
Zhang, Weiying ;
Ye, Lihong .
CANCER LETTERS, 2018, 415 :11-19
[9]   How Do You Identify m6 A Methylation in Transcriptomes at High Resolution? A Comparison of Recent Datasets [J].
Capitanchik, Charlotte ;
Toolan-Kerr, Patrick ;
Luscombe, Nicholas M. ;
Ule, Jernej .
FRONTIERS IN GENETICS, 2020, 11
[10]   Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression [J].
Chen, JiaLing ;
Du, Bin .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (01) :19-29
12345678910